Mike Donohue, PhD

Associate Professor of Neurology

Biography

Michael Donohue, PhD is an Associate Professor of Neurology, Associate Director of Biostatistics at the Alzheimer’s Therapeutic Research Institute (ATRI), and Co-Lead of the Biostatistics Unit of the Alzheimer’s Clinical Trial Consortium (ACTC). Since obtaining his PhD in Mathematics in 2005, Dr. Donohue has worked on Alzheimer’s clinical trials and observational studies, such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI). His primary area of interest is applying novel statistical methods to data from ADNI to better understand the multivariate course of markers of Alzheimer’s progression, and design innovative clinical trials to prevent or slow the progression of disease. He has studied the risk of cognitive decline associated with elevated brain amyloid in cognitively normal individuals; and helped design the first intervention in asymptomatic Alzheimer’s, the Anti-Amyloid Treatment for Asymptomatic Alzheimer’s (the A4 Study; in collaboration with Eli Lilly), and its primary outcome measure, the Preclinical Alzheimer Cognitive Composite. He has been awarded grants to develop innovative statistical approaches for Alzheimer’s from the National Institute on Aging; the Alzheimer’s Association, Michael J. Fox Foundation, and W. Garfield Weston Foundation; and the Clinical and Translation Research Institute of University of California, San Diego

Publications

Serratus anterior plane versus paravertebral nerve blocks for postoperative analgesia after non-mastectomy breast surgery: a randomized controlled non-inferiority trial Reg Anesth Pain Med. 2021 Sep; 46(9):773-778.

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial JAMA Neurol. 2021 Mar 01; 78(3):293-301.

Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study Alzheimers Dement (N Y). 2021; 7(1):e12135.

Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial Alzheimers Dement (Amst). 2021; 13(1):e12199.

Time between milestone events in the Alzheimer’s disease amyloid cascade Neuroimage. 2021 02 15; 227:117676.

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.